Multinational drug-maker Novartis is undertaking an investigation into unethical practices around the promotion of its diabetes drug Galvus, in india.
The company reportedly found some of its employees undertaking unethical promotions with wholesalers, and has launched a country-wide investigation. According to a media report, about 18 executives are under the scanner – a detail that Novartis did not comment on.
"In the instance mentioned the investigation is currently in progress and as a policy we do not comment on investigations which are in progress. It would therefore be premature to state what remedial action is being taken “ said Ranjit Shahani, Novartis Vice Chairman and Managing Director, in a statement from the company.
“Novartis has a strong Code of Conduct and Marketing Practices Guidelines with zero tolerance for deviations. We also carry out internal audits from time to time to assess the system and ensure that all safety checks are in place,” his statement said.